Corpus ID: 52312

GTI-2501. Lorus Therapeutics.

  title={GTI-2501. Lorus Therapeutics.},
  author={G. Tu and X. Tu},
  journal={Current opinion in investigational drugs},
  volume={2 10},
  • G. Tu, X. Tu
  • Published 2001
  • Medicine
  • Current opinion in investigational drugs
Lorus Therapeutics (formerly GeneSense Technologies) is developing GTI-2501, directed against the R1 component of ribonucleotide reductase, for the potential treatment of cancer [348928]. In November 2000, the company filed an IND with the FDA in preparation to begin a phase I trial in the US in the first quarter of 2001 [389975], [396537], [397960]. In March 2001, the FDA approved the IND application [402350], and in June 2001, a phase I, dose-escalating trial in patients with lymphomas or… Expand
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Targeting ribonucleotide reductase for cancer therapy
Ribonucleotide reductase inhibitors and future drug design.
Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.
[Ribonucleotide reductase and non-small cell lung cancer].
Antisense Therapeutics
Antisense approaches in drug discovery and development.